Replies to post #905 on Fate Therapeutics Inc (FATE)

[jondoeuk]

4-1BB is an activation marker and is not Treg-specific. So the ADR could engage all 4-1BB+ activated lymphocytes, including some Tregs (not all cancers will have Tregs that are 4-1BB+).

To selectively deplete Tregs, you would need additional specificity (e.g., CCR8) https://onlinelibrary.wiley.com/doi/10.1111/imm.13337

A number of mAbs (some CCR8-targeting) are in development https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3076 https://www.asco.org/abstracts-presentations/233962